Literature DB >> 24872585

Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen.

S Jegaskanda1, S H Ahn2, N Skinner3, A J Thompson4, T Ngyuen5, J Holmes5, R De Rose1, M Navis1, W R Winnall1, M Kramski1, G Bernardi1, J Bayliss6, D Colledge6, V Sozzi6, K Visvanathan3, S A Locarnini6, S J Kent1, P A Revill7.   

Abstract

UNLABELLED: The mechanisms by which hepatitis B virus (HBV) establishes and maintains chronic hepatitis B infection (CHB) are poorly defined. Innate immune responses play an important role in reducing HBV replication and pathogenesis. HBV has developed numerous mechanisms to escape these responses, including the production of the secreted hepatitis B e antigen (HBeAg), which has been shown to regulate antiviral toll-like receptor (TLR) and interleukin-1 (IL-1) signaling. IL-18 is a related cytokine that inhibits HBV replication in hepatoma cell lines and in the liver through the induction of gamma interferon (IFN-γ) by NK cells and T cells. We hypothesized that HBV or HBV proteins inhibit IFN-γ expression by NK cells as an accessory immunomodulatory function. We show that HBeAg protein inhibits the NF-κB pathway and thereby downregulates NK cell IFN-γ expression. Additionally, IFN-γ expression was significantly inhibited by exposure to serum from individuals with HBeAg-positive but not HBeAg-negative chronic HBV infection. Further, we show that the HBeAg protein suppresses IL-18-mediated NF-κB signaling in NK and hepatoma cells via modulation of the NF-κB pathway. Together, these findings show that the HBeAg inhibits IL-18 signaling and IFN-γ expression, which may play an important role in the establishment and/or maintenance of persistent HBV infection. IMPORTANCE: It is becoming increasingly apparent that NK cells play a role in the establishment and/or maintenance of chronic hepatitis B infection. The secreted HBeAg is an important regulator of innate and adaptive immune responses. We now show that the HBeAg downregulates NK cell-mediated IFN-γ production and IL-18 signaling, which may contribute to the establishment of infection and/or viral persistence. Our findings build on previous studies showing that the HBeAg also suppresses the TLR and IL-1 signaling pathways, suggesting that this viral protein is a key regulator of antiviral innate immune responses.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24872585      PMCID: PMC4178880          DOI: 10.1128/JVI.00111-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver.

Authors:  Michal Ganz; Timea Csak; Bharath Nath; Gyongyi Szabo
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

2.  Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.

Authors:  Eric T T L Tjwa; Gertine W van Oord; Joost P Hegmans; Harry L A Janssen; Andrea M Woltman
Journal:  J Hepatol       Date:  2010-09-06       Impact factor: 25.083

3.  Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids.

Authors:  Stefan F Wieland; Angelina Eustaquio; Christina Whitten-Bauer; Bryan Boyd; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-01       Impact factor: 11.205

4.  Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells.

Authors:  S Locarnini; T Shaw; J Dean; D Colledge; A Thompson; K Li; S M Lemon; G G K Lau; M R Beard
Journal:  J Clin Virol       Date:  2005-02       Impact factor: 3.168

5.  The hepatitis B e antigen suppresses IL-1β-mediated NF-κB activation in hepatocytes.

Authors:  R Wilson; N Warner; K Ryan; L Selleck; D Colledge; S Rodgers; K Li; P Revill; S Locarnini
Journal:  J Viral Hepat       Date:  2011-08-18       Impact factor: 3.728

6.  HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines.

Authors:  J F Schlaak; G Tully; H F Löhr; G Gerken; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

7.  Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures.

Authors:  Valérie Pasquetto; Stefan F Wieland; Susan L Uprichard; Marco Tripodi; Francis V Chisari
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

8.  Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice.

Authors:  Kiminori Kimura; Kazuhiro Kakimi; Stefan Wieland; Luca G Guidotti; Francis V Chisari
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

9.  Innate antiviral immune responses to hepatitis B virus.

Authors:  Malika Ait-Goughoulte; Julie Lucifora; Fabien Zoulim; David Durantel
Journal:  Viruses       Date:  2010-07-05       Impact factor: 5.818

10.  Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection.

Authors:  Dimitra Peppa; Lorenzo Micco; Alia Javaid; Patrick T F Kennedy; Anna Schurich; Claire Dunn; Celeste Pallant; Gidon Ellis; Pooja Khanna; Geoffrey Dusheiko; Richard J Gilson; Mala K Maini
Journal:  PLoS Pathog       Date:  2010-12-16       Impact factor: 6.823

View more
  21 in total

1.  Elevated pre-treatment IL-18 level is associated with HBeAg seroconversion in HIV-HBV coinfection.

Authors:  Yijia Li; Jing Xie; Huanling Wang; Yang Han; Nidan Wang; Chloe L Thio; Taisheng Li
Journal:  Antivir Ther       Date:  2017-02-14

2.  Hepatitis B e Antigen Inhibits NF-κB Activity by Interrupting K63-Linked Ubiquitination of NEMO.

Authors:  Yuan Wang; Lei Cui; Guifang Yang; Jianbo Zhan; Liang Guo; Yu Chen; Chengpeng Fan; Dan Liu; Deyin Guo
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 3.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

4.  Differential Expression of CX3CL1 in Hepatitis B Virus-Replicating Hepatoma Cells Can Affect the Migration Activity of CX3CR1+ Immune Cells.

Authors:  Yasuteru Kondo; Osamu Kimura; Yasuhito Tanaka; Masashi Ninomiya; Tomoaki Iwata; Takayuki Kogure; Jun Inoue; Masaya Sugiyama; Tatsuki Morosawa; Yasuyuki Fujisaka; Tooru Shimosegawa
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

Review 5.  Overview of hepatitis B viral replication and genetic variability.

Authors:  Shuping Tong; Peter Revill
Journal:  J Hepatol       Date:  2016-04       Impact factor: 25.083

6.  Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation.

Authors:  Bidisha Mitra; Jinyu Wang; Elena S Kim; Richeng Mao; Minhui Dong; Yuanjie Liu; Jiming Zhang; Haitao Guo
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

7.  The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B.

Authors:  Yi He; Yingzhi Zhou; Huimin Wang; Xiaorong Peng; Yunan Chang; Peng Hu; Hong Ren; Hongmei Xu
Journal:  BMC Pediatr       Date:  2022-07-20       Impact factor: 2.567

Review 8.  Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections.

Authors:  Xuefen Li; Xia Liu; Li Tian; Yu Chen
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 9.  Crosstalk between innate and adaptive immunity in hepatitis B virus infection.

Authors:  Li Wang; Kai Wang; Zhi-Qiang Zou
Journal:  World J Hepatol       Date:  2015-12-28

Review 10.  Innate immune targets of hepatitis B virus infection.

Authors:  Zhi-Qiang Zou; Li Wang; Kai Wang; Ji-Guang Yu
Journal:  World J Hepatol       Date:  2016-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.